Society Testimony

Testimony to FDA on Semaglutide

October 17, 2017

Endocrine Society Submitted Testimony to the Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee 

"The Society urges the FDA to give fair consideration of new options in combating this disease and to expedite the approval process for emerging therapies that, based on safety and efficacy data, have the potential to reduce complications and impact the progression of diabetes. "

arrow Read the Full Testimony

Last Updated:

Policy Communications

Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.